Petros Giannikopoulos is the Director of the IGI Clinical Laboratory, a CLIA-certified laboratory that is accredited by the College of American Pathologists to perform high-complexity molecular testing. His research focuses on the development and deployment of laboratory-developed companion diagnostics for novel CRISPR-based genomic therapies.
Petros is board-certified in anatomic, pediatric, and molecular genetic pathology, and is a Fellow of the College of American Pathologists. Before joining the IGI, he was a health technology entrepreneur and also served as Laboratory Director for multiple next-generation sequencing (NGS)-based clinical genomics labs in the US and in Asia. He obtained his MD from Harvard Medical School, completed his pathology residency at the University of California, San Francisco, and trained in pediatric and molecular pathology at Texas Children’s Hospital and Harvard Medical School, respectively.